Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Return on Capital Employed (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Return on Capital Employed for 15 consecutive years, with 0.07% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 19.0% to 0.07% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.07%, a 19.0% decrease, with the full-year FY2025 number at 0.06%, down 4.0% from a year prior.
  • Return on Capital Employed was 0.07% for Q4 2025 at Anika Therapeutics, down from 0.1% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.12% in Q1 2025 to a low of 0.11% in Q1 2021.
  • A 5-year average of 0.01% and a median of 0.0% in 2022 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: decreased -21bps in 2021, then rose 12bps in 2024.
  • Anika Therapeutics' Return on Capital Employed stood at 0.01% in 2021, then soared by 40bps to 0.01% in 2022, then crashed by -73bps to 0.0% in 2023, then skyrocketed by 3743bps to 0.12% in 2024, then crashed by -154bps to 0.07% in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Return on Capital Employed are 0.07% (Q4 2025), 0.1% (Q3 2025), and 0.11% (Q2 2025).